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Abstract
Background: Oxaliplatin-based chemotherapy has been linked to the development of sinusoidal
obstruction syndrome (SOS), which is detrimental to outcome after liver resection for colorectal liver
metastases (CLM). The aim of this study was to determine how the expression of genes involved in the
transport and metabolism of FOLFOX chemotherapy impacts on tissue injury in a murine model of CLM.
Methods: Experimental CLM was established in C57/B16 mice and treated with FOLFOX chemo-
therapy. After 3 weeks, the animals were killed and RNA extracted from liver, spleen and tumour tissue.
DNA damage was assessed by immunohistochemistry for gH2AX. Gene expression was determined by
reverse transcriptase polymerase chain reaction.
Results: FOLFOX treatment was associated with an increase in the number of gH2AX-positive cells in
both the spleen (P < 0.01) and tumour tissue (P < 0.01), but not the liver. Tissue resistance to injury
following FOLFOX was associated with high expression of the copper transporter ATP7B. Differences in
the expression of genes related to 5-fluorouracil metabolism or DNA repair did not correlate with the
severity of tissue injury.
Conclusions: High levels of expression of ATP7B are associated with resistance to tissue injury follow-
ing FOLFOX chemotherapy. Polymorphisms in the ATP7B gene may explain varying susceptibility to SOS
among patients following oxaliplatin-based chemotherapy.
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Introduction
The use of oxaliplatin-based chemotherapy prior to resection of
colorectal liver metastases (CLM) has been associated with the
development of sinusoidal obstruction syndrome (SOS) in the
non-tumour-bearing liver in up to 45% of patients.1–4 The pres-
ence of SOS is a cause for concern in major liver resection and the
use of oxaliplatin-based chemotherapy prior to resection of CLM
has been associated with a significant increase in perioperative
morbidity.1,5 More recently, it has been suggested that the presence
of SOS is associated with poorer disease-specific survival and, in
particular, an increased risk for intrahepatic recurrence.2 Thus,
there is an urgent need to identify those patients with particular
risk for developing SOS in order to ensure that their exposure to
oxaliplatin-based chemotherapy is minimized.
Over the last few years, several attempts have been made to
develop a murine model of oxaliplatin-induced SOS. However, to
date, none of these have been successful in inducing histological
changes in the liver despite the administration of high doses of
chemotherapy for prolonged periods.6,7 One potential explanation
for this observation is found in early pharmacological studies
conducted in healthy mice, which showed the spleen to be the
primary organ to take up oxaliplatin and indicated that reduced
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concentrations are taken up by the liver.8 Identification of the
factors responsible for the relative resistance of the murine liver to
oxaliplatin may represent an important step towards establishing
why some patients seem particularly vulnerable to the toxic effects
of this drug.
Oxaliplatin is a third-generation platinum compound consist-
ing of a platinum atom conjugated to diaminocyclohexane and
oxalate groups.9 Work by Katano et al. and Safaei et al. demon-
strated, in cancer cell lines, that the cellular influx and efflux
kinetics of platinum compounds mirror those of copper.10,11 Cel-
lular uptake of copper is regulated by the plasma membrane
copper transporters CTR1 and CTR2. Cell lines which do not
express CTR1 demonstrate high levels of resistance to platinum-
based chemotherapeutics, which strongly suggests that this trans-
porter plays a critical role in the cellular uptake of these drugs.12,13
In support of this observation, it has been demonstrated in vivo
that dorsal root ganglia with high CTR1 expression are particu-
larly vulnerable to oxaliplatin toxicity.14 By contrast, high levels of
expression of the copper uptake transporter CTR2 have been
shown to be associated with relative resistance to platinum-based
chemotherapy both in vitro and in vivo in ovarian cancer.15–17
The cellular export of copper is regulated by the transmembrane
ATPases ATP7A and ATP7B. Cancer cell lines which demonstrate
resistance to platinum-based chemotherapy commonly express
high levels of these transporters, thereby preventing the intracellu-
lar accumulation of platinum.10,18,19 The validity of these in vitro
observations has been confirmed in vivo: patients with colorectal
cancer, in which high levels of ATP7B are expressed, are more likely
to experience disease progression during treatment than those with
low levels of ATP7B expression (hazard ratio 3.56; P < 0.01).20
Oxaliplatin is rarely administered as monotherapy, but, rather,
is used alongside a thymidylate synthase inhibitor such as
5-flourouracil (5-FU) or leucovorin (in FOLFOX) or the oral
pro-drug capecitabine (in CAPOX/XELOX).21 Upon cellular entry,
5-FU is converted into its active metabolites by the action of the
enzyme thymidine phosphorylase (TP). These metabolites exhibit
a cytotoxic effect through the inhibition of the enzyme thymidylate
synthase (TS). Many cells also possess the capability to convert
5-FU into biologically inactive metabolites via a pathway that
utilizes the enzyme dihydropyrimidine dehydrogenase (DPD).22
The aim of the current study was to determine the differential
expression of genes involved in the cellular transport of platinum
compounds and tissue injury following exposure to FOLFOX
chemotherapy.
Materials and methods
The use of animals in this study was approved by the local research
ethics committee and the UK Home Office.
Experimental model of CLM
Following isoflurane anaesthesia, C57/Bl6 mice underwent
midline laparotomy. Subcapsular injection of the syngeneic
MCA38 colorectal cancer cell line, stably transfected with the
pGL4.51 luciferase reporting vector (Promega UK, Southampton,
UK), was then performed in the left lobe of the liver (105 cells per
animal suspended in 10 ml of Hank’s buffered salt solution). The
injection track was sealed with manual compression to achieve
haemostasis followed by application of butylcyanoacrylate glue
(Indermil®; Henkel Ireland Ltd, Dublin, Ireland). The abdomen
was closed in two layers with vicryl.
Five days following surgery, the presence of viable tumour was
confirmed using the IVIS® Imaging System (Caliper Life Sciences,
Hopkinton, MA, USA). At this point, treatment was commenced
with intraperitoneal FOLFOX chemotherapy, which consisted of
6 mg/kg oxaliplatin followed 2 h later by 50 mg/kg 5-FU and
90 mg/kg folinic acid. This drug regimen was based on a review of
the literature and the present group’s own preliminary toxicity
studies. Control animals received vehicle (10% DMSO) alone.
Animals were treated weekly for 3 weeks with FOLFOX and
killed 24 h after the final dose of chemotherapy. There were five
animals in each experimental group.
Histology and immunohistochemistry
Sections of 5 mm were cut from formalin-fixed, paraffin-
embedded blocks of liver, spleen and tumour tissue from each
animal. One of these sections was stained with haematoxylin and
eosin (H&E) in order to facilitate an assessment of drug-induced
tissue injury.
To assess chemotherapy-induced DNA damage in each of these
tissues, immunohistochemistry was performed for gH2AX. In
brief, sections were deparaffinized and peroxidase activity
blocked. Antigen retrieval was performed with 1 mm EDTA
pH 8.0, following which endogenous biotin was blocked by use of
a commercial kit (Vector Laboratories, Inc., Burlingame, CA,
USA) before incubation in 20% swine serum for 30 min. The
primary antibody (#9718; Cell Signalling Technology, Inc.,
Danvers, MA, USA) was added at a concentration of 1 : 100 and
sections incubated overnight at 4 °C. Sections were then incu-
bated for 90 min with a biotin-conjugated secondary antibody
(Dako UK Ltd, Ely, UK) and for 45 min with streptavidin
biotin-peroxidase conjugate (Vector Laboratories, Inc.). 3,3′-
diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories,
Inc.) was used as the chromogen. The numbers of positive stained
cells in 15 separate high-power fields (HPF; magnification ¥20)
were counted in a blinded manner.
Reverse transcription polymerase chain reaction
RNA was extracted from snap frozen samples of liver, spleen and
tumour from each animal using the RNeasy system according to
the manufacturer’s instructions (Qiagen Ltd, Crawley, UK). RNA
was quantified on a spectrophotometer and 1 mg used to generate
cDNA using Moloney murine leukaemia virus reverse tran-
scriptase (RT) and a random hexamer primer (Promega UK) to a
final total volume of 50 ml.
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Reactions consisted of 12.5 ml polymerase chain reaction (PCR)
mastermix, 400 nM each of forward and reverse primers and 1 ml
of cDNA to a final volume of 25 ml. Amplification was performed
using 35 cycles consisting of denaturation at 95 °C, annealing at
55 °C and elongation at 70 °C, each step of which lasted 30 s. This
was followed by a final elongation step at 70 °C for 7 min. The
PCR product was then run on 1% agarose gel and detected by
staining with ethidium bromide. b-Actin served as the internal
control. Primer sequences are listed in Table S1 (online).
Statistical analysis
Data are presented as the mean standard error. Statistical sig-
nificance was assessed using Kruskall–Wallis one-way analysis of
variance (anova) and the Mann–Whitney U-test as appropriate.
A P-value of <0.05 was considered to indicate statistical signifi-
cance.
Results
FOLFOX-induced tissue injury
Intraperitoneal administration of FOLFOX demonstrated antitu-
mour efficacy in this model, with significant areas of cell death
seen on the review of H&E-stained sections (Fig. 1a). In keeping
with previous reports, there was no histological evidence of SOS.
As the spleen has been reported to be the main organ to take up
oxaliplatin-based chemotherapy in pharmacological studies, sec-
tions of this organ were also reviewed. These revealed atrophy of
the germinal centre of the spleen and relative expansion of the red
pulp (Fig. 1b).
The toxic effects of oxaliplatin are mediated through the
binding of platinum to DNA, which results in the formation of
DNA double-strand breaks and either activation of the cellular
DNA repair mechanisms or, if sufficient damage is present,
programmed cell death. In order to determine whether the histo-
logical changes observed in the tumour and spleen were a conse-
quence of DNA damage, immunohistochemistry was performed
for gH2AX. There was a significant increase in the number of
gH2AX-positive cells in both the spleen (38 versus nine cells per
HPF; P < 0.01) (Fig. 2a) and tumour tissue (51 versus 38 cells per
HPF; P < 0.01) (Fig. 2b) of FOLFOX-treated animals, whereas no
such increase was demonstrated in the liver (four versus five cells
per HPF) (Fig. 2c). Together, these observations would appear to
support the assertion that the murine liver is relatively resistant to
FOLFOX-induced injury, whereas the spleen and tumour tissue
are more vulnerable.
(a)
(b)
Figure 1 (a) Histopathology demonstrated areas of tumour death in FOLFOX-treated animals compared with control animals, confirming the
efficacy of this regimen. (b) Evidence of splenic injury with loss of germinal centres and relative expansion of the red pulp was also apparent.
(Haematoxylin and eosin stain; original magnification ¥10)
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Copper transporter expression
To assess the relationship between the ability of tissues to take up
oxaliplatin-based chemotherapy and the development of histo-
logical injury, RT-PCR was performed to determine the expres-
sion of the copper influx (CTR1 and CTR2) and efflux (ATP7A
and ATP7B) transporters. Despite the absence of injury to the
liver, mRNA expression of the influx transporters was such as
might be expected in an oxaliplatin-sensitive organ (i.e. high
expression of CTR1 and relatively low expression of CTR2)
(Fig. 3). Overall, the transcript level of these transporters was
similar to that seen in oxaliplatin-sensitive tumour tissue.
Together, these findings would suggest that the resistance of the
murine liver to FOLFOX-induced injury in this model is not a
consequence of a deficiency in oxaliplatin uptake.
The mRNA expression of the efflux transporter ATP7A in the
liver was somewhere between those of the tumour and spleen,
again suggesting that this is not pivotal in mediating resistance to
oxaliplatin-induced injury. By contrast, mRNA expression of
ATP7B was markedly higher in the liver than in the other tissues,
which suggests that the liver may be able to rapidly export
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Figure 2 Immunohistochemistry for gH2AX revealed FOLFOX-induced DNA damage in the (a) spleen and (b) tumour tissue. (c) This damage
was not seen in the liver. HPF, high-power field
Figure 3 Expression of copper transporter genes in liver, spleen and tumour tissue
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oxaliplatin, thereby providing a mechanism through which intra-
cellular exposure to the drug is limited and thus minimizing tox-
icity (Fig. 3).
5-FU metabolism
In order to assess the relative sensitivity of the liver to the 5-FU
component of the chemotherapy regimen, expression of TS, TP
and DPD were compared across all three tissues. The liver was
found to express the highest amount of TP transcript, suggesting
there should be no deficiency in converting 5-FU into its active
metabolites. The expression of DPD was similar in liver and
tumour tissue, and the expression of TS was similar across all
three tissues (Fig. 4). It therefore seems unlikely that 5-FU resist-
ance prevents the development of histological liver injury in this
model.
Nucleotide excision repair pathway
The cellular response to DNA–platinum adducts is to attempt
repair by making use of the nucleotide excision repair (NER)
pathway in which, following recognition of DNA damage, the
DNA helix is unwound to allow excision of the damaged DNA by
proteins including ERCC1/2 and XPF. Following excision, the
damaged DNA is resynthesized by DNA polymerase and the helix
rewinds. Impairment of the NER pathway is associated with
increased sensitivity to oxaliplatin-mediated DNA damage.23,24 It
has recently been suggested that decreased expression of ERCC2
transcript may be associated with the development of SOS in
patients with CLM treated with preoperative chemotherapy.25
In the current model, mRNA expression of the NER compo-
nents ERCC1/2 and XPF in the liver was generally lower than that
seen in tumour tissue, but was broadly similar to that seen in the
spleen (Fig. 5). This would seem to suggest that differences in this
regard are not responsible for the relative resistance of the murine
liver to FOLFOX.
Discussion
This study has confirmed the observation that the murine liver
appears to be relatively resistant to the development of injury
following exposure to FOLFOX chemotherapy. By contrast, the
spleen, along with implanted tumour tissue, appears to be par-
ticularly sensitive. By comparing the expression of various genes
in these sensitive tissues with that of the liver, this study has been
able to demonstrate that this resistance appears to be related to
high expression of the copper efflux transporter ATP7B, which
Figure 4 Expression of genes related to 5-fluorouracil metabolism in liver, spleen and tumour tissue. TS, thymidylate synthase; TP, thymidine
phosphorylase; DPD, dihydropyrimidine dehydrogenase
Figure 5 Expression of genes from the nucleotide excision repair pathway
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enables the rapid clearance of oxaliplatin from the liver. There
were no differences in the expression of genes related to 5-FU
metabolism or the NER pathway which would otherwise explain
this resistance.
The liver plays a central role in copper homeostasis; in particu-
lar, its export is tightly regulated by the liver through the actions of
ATP7B, which transfers copper to the secretory pathway whereby
it is conjugated to caeruloplasmin or, when copper is in excess, is
regulated through biliary excretion.26,27 For example, Wilson’s
disease is characterized by excessive hepatic accumulation of
copper and occurs as a result of a functional deficit in the ATP7B
gene.27 As already discussed, ATP7B also plays a key role in the
cellular export of platinum compounds, the overexpression of
which is associated with chemo-resistance in cancer cell lines.19 As
ATP7B is normally highly expressed in the liver, it would be rea-
sonable to expect that it would also be relatively protected from
the platinum toxicity.
Polymorphisms in the gene ATP7B are relatively common in the
general population. One study that examined genomic DNA iso-
lated from the peripheral leukocytes of 203 cancer patients found
that 61 patients had a polymorphism in ATP7B.28 This study made
no attempt to correlate these polymorphisms with chemotherapy
side-effects, however, and thus the functional consequence of such
polymorphisms is unknown.
Although it is entirely logical to believe there is a direct corre-
lation between the number of cycles of chemotherapy adminis-
tered to patients and the development of SOS, the evidence for
this is not particularly clear. In a multivariate analysis performed
in a series of 90 patients undergoing resection of CLM following
preoperative chemotherapy, Nakano et al. identified the receipt of
more than six cycles of oxaliplatin-based chemotherapy as an
independent risk factor for the development of SOS.29 By contrast,
a separate study of 196 patients, conducted by Tamandl et al.,
failed to identify any association between the number of chemo-
therapy cycles and SOS development.2 One possible explanation
for these divergent observations is that pharmacogenomics and, in
particular, polymorphisms affecting ATP7B function may play a
key role in determining individual susceptibility to the toxic
effects of oxaliplatin-based chemotherapy.
The concept of modifying a chemotherapy strategy based on
the presence of genetic polymorphisms is not new. Irinotecan is
an alternative chemotherapeutic widely applied in the manage-
ment of patients with CLM, the use of which can be associated
with several significant complications, including febrile neutro-
penia and severe diarrhoea. The active metabolite of irinotecan,
SN38, undergoes metabolism itself utilizing a group of enzymes
known as UDP-glucuronosyltransferase (UGT) 1A. Single-
nucleotide polymorphisms (SNPs) in the genes encoding
members of this family are common and, when present, particu-
larly in the gene UGT1A1, have been associated with an
increased incidence of irinotecan toxicity. When these SNPs are
detected, it is usual practice to reduce the administered dose of
irinotecan.30,31
The identification of a cohort of individuals at high risk for
developing SOS following oxaliplatin-based chemotherapy would
be extremely useful in establishing which patients will be best
served by the provision of alternative and equally effective regi-
mens in place of prolonged and detrimental chemotherapy.
Screening for SNPs is an attractive way of doing this as genomic
DNA can be easily isolated from peripheral blood leukocytes for
analysis.
It should be noted that the current study is intended to generate
hypotheses rather than to provide a direct causative link between
ATP7B expression and the occurrence of oxaliplatin-induced SOS.
Nonetheless, despite these limitations, it does appear to offer jus-
tification for human studies to explore whether SNPs in ATP7B
could be used to identify a cohort of patients at high risk for
oxaliplatin-induced SOS.
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